Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2012-08-23 Interim / Quarterly Rep…
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport januari – juni 2012' (Interim Report January – June 2012) for Karolinska Development AB. It contains comprehensive financial statements, including income statements, balance sheet summaries, and detailed management commentary on business performance and portfolio developments. It is clearly a substantive financial report for a period shorter than a full fiscal year, not an announcement or a certification. H2 2012
2012-08-23 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'Interim report January – June 2012' for Karolinska Development AB. It contains comprehensive financial statements, including income statements, balance sheets, and earnings per share data for the specified period. It also includes management commentary and portfolio updates. As it is a comprehensive financial report for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report (IR). H1 2012
2012-08-23 English
Pergamum reports top line Phase II-data from the clinical trial for prevention of post-surgical adhesions
Earnings Release Classification · 1% confidence The document is a press release dated July 10, 2012, announcing the top-line results from a Phase II clinical trial (PXL-01) for Pergamum AB. It details the study outcomes (primary endpoint not met, but positive trends observed in secondary measures) and provides context about the disease and future steps. This format—a news announcement summarizing key data points from a study—is characteristic of an Earnings Release (ER) or a general announcement. Since it is specifically reporting on clinical trial data and results, it is best classified as an announcement of results. While it is not a formal 'Earnings Release' in the sense of quarterly financial performance, in the context of biotech/pharma filings, major clinical data announcements often fall under the general 'Earnings Release' category (ER) if they are the primary driver of market news, or sometimes 'Regulatory Filings' (RNS). Given the structure, it is a direct announcement of material information. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). It is a direct announcement of results, making ER the most appropriate fit among the provided options for a material announcement, although it is not strictly financial earnings. Q3 2012
2012-07-10 English
Pergamum rapporterar första fas II-data från den kliniska studien för förebyggande av skadlig ärrbildning efter kirurgi
Regulatory Filings Classification · 1% confidence The document is a press release dated July 10, 2012, announcing the first results from a Phase II clinical study (PXL-01) for Pergamum AB. It details the study's primary endpoint outcome (not met), safety profile, and secondary efficacy trends regarding hand mobility after surgery. This type of announcement, which provides key financial/operational results for a specific period or event (in this case, clinical trial data), most closely aligns with an Earnings Release (ER) if it were quarterly results, or a general Regulatory Filing (RNS) if it doesn't fit elsewhere. Since it is a specific operational update (clinical trial results) rather than a standard quarterly financial report (10-K or IR), and it is not a transcript (CT), presentation (IP), or management discussion (MDA), it falls best under the general category for significant operational announcements that aren't explicitly covered. However, given the context of financial reporting databases, clinical trial updates that release key performance indicators often function similarly to an Earnings Release for biotech/pharma companies, but since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is clinical data, the most appropriate general category for a significant, non-standard operational announcement is Regulatory Filings (RNS), as it is a public disclosure of material information not covered by other specific codes. It is not a report itself, but an announcement of findings.
2012-07-10 Swedish
Karolinska Development genomför aktiebyte med Industrifonden
M&A Activity Classification · 1% confidence The document is a press release from Karolinska Development AB announcing a specific transaction: an exchange of shareholdings in two other companies (Oncopeptides AB and Aprea AB) with Industrifonden. This transaction involves changes in ownership structure and asset allocation, which falls under corporate financing or major corporate actions. Reviewing the definitions, the most fitting category is 'Capital/Financing Update' (CAP), as it details a significant change in the company's capital structure via asset exchange, rather than a general regulatory filing (RNS) or a management change (MANG). It is not an earnings release (ER), dividend notice (DIV), or a standard M&A takeover bid (TAR), but a specific financing/asset restructuring deal. Given the nature of the announcement regarding asset exchange and control acquisition, CAP is the best fit.
2012-06-13 Swedish
Karolinska Development arranges a share ownership exchange with Industrifonden
M&A Activity Classification · 1% confidence The document is an announcement dated June 13, 2012, detailing an 'ownership exchange' between Karolinska Development AB and Industrifonden involving shares in Oncopeptides AB and Aprea AB. This transaction results in a change in control/significant holding (Karolinska Development gaining 69.4% of Aprea AB) and involves the exchange of shareholdings. This clearly falls under the category of corporate actions related to mergers, acquisitions, or significant asset/share transfers. Based on the provided definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification, as it covers merger proposals or takeover bids, which this share exchange transaction closely resembles in its nature of transferring control/significant stakes between entities.
2012-06-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.